GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Intangible Assets
中文

Agenus (Agenus) Intangible Assets : $29.1 Mil (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Agenus Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Agenus's intangible assets for the quarter that ended in Dec. 2023 was $29.1 Mil.


Agenus Intangible Assets Historical Data

The historical data trend for Agenus's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Intangible Assets Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.69 36.34 33.36 31.70 29.13

Agenus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.70 31.28 29.71 29.16 29.13

Agenus Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Agenus  (NAS:AGEN) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Agenus Intangible Assets Related Terms

Thank you for viewing the detailed overview of Agenus's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (Agenus) Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Executives
Ulf Wiinberg director
Steven J O'day officer: Chief Medical Officer 2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen officer: Chairman & CEO 3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin officer: VP Finance 3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss officer: Chief Legal Officer 139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch director 280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp 10 percent owner 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan officer: Chief Technology Officer 3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns officer: V.P. and General Counsel AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell officer: Chief Operating Officer 3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis director FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan director ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010